Salmeterol

Generic Name: Salmeterol

Brand Names: Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 89365-50-4

Unique Ingredient Identifier: 2I4BC502BT

Background: Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.

Salmeterol was granted FDA approval on 4 February 1994.

Indication: 用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。

Associated Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

Clinical Trials

Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years

Phase 3

Conditions: Asthma

Interventions: Drug: fluticasone/ salmeterol
Drug: Fluticasone/ Formoterol

First Posted Date: 2018-01-02

Last Posted Date: 2019-04-29

Lead Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd

Target Recruit Count: 330

Registration Number: NCT03387241

Locations: 🇨🇳
China-Japanese Friendship Hospital, Beijing, Beijing, China

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone propionate
Drug: Tiotropium
Drug: Salmeterol
Drug: Olodaterol

First Posted Date: 2017-08-07

Last Posted Date: 2020-04-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 302

Registration Number: NCT03240575

Locations: 🇺🇸
Pulmonary Rsrch Inst of SE MI, Farmington Hills, Michigan, United States
🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 39 locations

Cardiovascular Function in COPD Patients

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone propionate
Drug: Tiotropium
Drug: Salmeterol
Drug: Olodaterol

First Posted Date: 2017-02-16

Last Posted Date: 2019-08-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 76

Registration Number: NCT03055988

Locations: 🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany
🇩🇪
Klinische Forschung Berlin GbR, Berlin, Germany
🇩🇪
Praxis Dr. med. Claus Keller, Frankfurt, Germany

and more 7 locations

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: UMEC/VI 62.5/25 mcg via ELLIPTA
Drug: UMEC 62.5 mcg via ELLIPTA
Drug: Salmeterol 50 mcg via DISKUS
Drug: Placebo via DISKUS
Drug: Placebo via ELLIPTA

First Posted Date: 2017-01-27

Last Posted Date: 2020-03-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2696

Registration Number: NCT03034915

Locations: 🇸🇪
GSK Investigational Site, Örebro, Sweden

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

Phase 2

Completed

Conditions: Submental Fat

Interventions: Drug: LIPO-202
Drug: Placebo for LIPO-202

First Posted Date: 2016-12-29

Last Posted Date: 2017-10-20

Lead Sponsor: Neothetics, Inc

Target Recruit Count: 162

Registration Number: NCT03005717

Locations: 🇺🇸
Juva Skin & Laser Center, New York, New York, United States
🇺🇸
Clinical Testing of Beverly Hills, Beverly Hills, California, United States
🇺🇸
Ablon Skin Institute And Research Center, Manhattan Beach, California, United States

and more 8 locations

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

Phase 2

Completed

Conditions: Central Abdominal Bulging

Interventions: Drug: Placebo
Drug: LIPO-202

First Posted Date: 2015-10-05

Last Posted Date: 2015-12-24

Lead Sponsor: Neothetics, Inc

Target Recruit Count: 120

Registration Number: NCT02568319

Locations: 🇺🇸
Diagnamics, Inc., Encinitas, California, United States
🇺🇸
Ablon Skin Institute and Research Center, Manhattan Beach, California, United States
🇺🇸
Tennessee Clinical Research Center, Nashville, Tennessee, United States

and more 3 locations